Improvements such as these have previously been reported in small European studies, in which natalizumab was associated with decreased fatigue [13], a reduction in cognitive impairment [31], and improvements in mobility and reduced disease activity in patients previously treated with interferon beta or glatiramer acetate [32]. This evidence concerns the gene IFNB1 and Cognitive impairment.